The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †.

与PanOptix3†相比，新的全视距IOL*1提供了出色的距离视觉2和14%的可读打印尺寸。

93% of patients become free from glasses at all distances.#4 ‡

93%的患者在任何距离都不戴眼镜#4‡

TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes.5¶

TECNIS Odyssey IOL对残余屈光不正具有更高的耐受性，使外科医生能够提供一致和可靠的患者结果

JACKSONVILLE, Fla., Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson§, a global leader in eye health, has announced it's expanding the roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC - IOL), TECNIS Odyssey, in the U.S. The new full visual range IOL*1 offers patients unmatched continuous full range of vision‖¶¶6, so they can see clearly from far to near and in between, minimizing their need for glasses 3,6 †‖# . TECNIS Odyssey IOL is built on the TECNIS platform, providing two-times better contrast in low lighting than PanOptix.7,8 † In addition, TECNIS Odyssey IOL patients are able to read 14% smaller print on average than PanOptix IOL patients2 † and 93% reported no or mild halos, glare, or starbursts one month after surgery9..

佛罗里达州杰克逊维尔，2024年9月30日/PRNewswire/--全球眼科健康领导者强生公司宣布，将扩大其在美国TECNIS Odyssey老视矫正人工晶状体（PC-IOL）方面的最新进展。新的全视野IOL*1为患者提供无与伦比的连续全视野‖¶¶6，因此他们可以从远到近以及两者之间清晰地看到，最大程度地减少了他们对眼镜的需求3,6†‖‖‖。TECNIS Odyssey IOL建立在TECNIS平台上，在低光照下比PanOptix提供了两倍的对比度。7,8†此外，TECNIS Odyssey IOL患者比PanOptix IOL患者平均能够阅读14%的印刷品2†，93%的患者在手术后一个月报告没有或轻微的光晕，眩光或星爆9。。

Experience the full interactive Multichannel News Release here: https://www2.multivu.com/johnson-johnson/9293351-en-johnson-and-johnson-vision-tecnis-odyssey

在此体验全互动多渠道新闻发布：https://www2.multivu.com/johnson-johnson/9293351-en-johnson-and-johnson-vision-tecnis-odyssey

'More than 14,000 eyes have already benefited from TECNIS Odyssey, our new full visual range IOL1. TECNIS Odyssey patients have reported outstanding visual outcomes following surgery, which is why we are excited to announce we are expanding the roll-out across the U.S. today,' said Peter Menziuso♠, Company Group Chairman, Vision, Johnson & Johnson.

Peter Menziuso说：“超过14000只眼睛已经从TECNIS Odyssey中受益，TECNIS Odyssey是我们新的全视野IOL1。TECNIS Odyssey患者在手术后报告了出色的视力结果，这就是为什么我们很高兴宣布我们今天将在美国各地扩大推广的原因。”♠, 强生公司愿景集团董事长。

'Cataract surgery gives patients a once in a lifetime opportunity to improve their sight, and now with this advanced IOL, patients can see clearly at every distance, without the need for glasses.'.

。

It is estimated that 20.5 million (17.2%) Americans aged 40 years and older have a cataract in one or both eyes, yet only 6.1 million (5.1%) have had cataract surgery.10 Left untreated, cataracts cause vision to deteriorate over time. Many people who have cataracts experience other problems with their vision, such as presbyopia, which is a progressive eye condition that makes it difficult to focus on close objects and usually becomes noticeable around 40 years of age.11 Full visual range IOLs provide the opportunity to correct presbyopia at the time of cataract surgery..

。许多患有白内障的人会遇到其他视力问题，例如老视，这是一种渐进性的眼部疾病，难以聚焦在近距离物体上，通常在40岁左右变得明显。11全视力人工晶状体为白内障手术时纠正老视提供了机会。。

'The TECNIS Odyssey IOL is perhaps the most comprehensive and well-balanced PC-IOL on the market to date,' said Dr. George O. Waring IV**, Medical Director of the Waring Vision Institute in Mt. Pleasant, SC. 'It falls under a new standard of full vision range that provides extraordinary contrast in both day and night-time conditions, tolerance to refractive error and minimal dysphotopsias with outstanding contrast sensitivity** that really takes it to a whole different level and nothing like we've seen before with prior PC-IOLs'..

“TECNIS Odyssey IOL可能是迄今为止市场上最全面、最平衡的PC-IOL，”南卡罗来纳州普莱森特市沃林视觉研究所医学主任乔治·沃林四世博士说。“它属于全视力范围的新标准，在白天和夜间条件下都能提供非凡的对比度，对屈光不正的耐受性和最小的视力异常，具有出色的对比敏感度**，真正将其提升到一个完全不同的水平，这与我们以前的PC-IOL相比是前所未有的。”。。

The new TECNIS Odyssey full visual range IOL*1 was built with proprietary technology that results in superior¶¶ image quality, delivering sharp vision even in challenging lighting conditions7 ,8 ††‡‡. The design also delivers fewer visual disturbances for enhanced night-time visual quality12¶¶:

新的TECNIS Odyssey全视距IOL*1采用专有技术制造，可产生卓越的图像质量，即使在具有挑战性的照明条件下也能提供清晰的视觉7,8。该设计还可以减少视觉干扰，提高夜间视觉质量12¶¶：

Precise vision: TECNIS Odyssey IOL ensures crisp and clear vision, allowing patients to see with clarity at every distance - whether they are reading, driving or engaging in daily activities.6 ,7 ,8 *†‖94% of patients were satisfied with their overall vision without glasses.At every distance: Its unique, freeform diffractive surface was designed to eliminate the gaps between near, intermediate and far distances, and offer continuous, uninterrupted vision at all distances.6 †‖96% of patients were satisfied with reading a smartphone or tablet14, and 97% were satisfied with distance vision.13In any lighting: Engineered to minimize night vision disturbances – fewer halos and glare12 ¶¶ TECNIS Odyssey IOL provides better image quality than PanOptix day and night, for a more comfortable night-time experience7,8 ††‡‡.92% of patients were satisfied with their ability to see steps at night14 and read street signs at night 14.As part of this roll-out, J&J is launching 'TECNIS Odyssey IOL Peer Connect'.

精确的视力：TECNIS Odyssey IOL确保了清晰清晰的视力，使患者无论是阅读、驾驶还是从事日常活动，都能清晰地看到每一段距离。6,7,8*†‖94%的患者对不戴眼镜的整体视力感到满意。在每一个距离：其独特的自由衍射表面旨在消除近距离、中距离和远距离之间的差距，并在所有距离提供连续、不间断的视觉。96%的患者对阅读智能手机或表格感到满意，97%的患者对远距视觉感到满意。13在任何照明中：旨在最大程度地减少夜视干扰-减少光晕和眩光12¶TECNIS Odyssey IOL提供比PanOptix昼夜更好的图像质量，以获得更舒适的夜间体验7,8†††‡‡‡‡。92%的患者对他们在夜间看到台阶14和阅读街道标志的能力感到满意晚上14点。作为此次推出的一部分，强生公司将推出“TECNIS Odyssey IOL Peer Connect”。

This initiative was designed to foster direct and meaningful medical and scientific conversations regarding TECNIS Odyssey IOL between healthcare professionals with expert surgeons who had early access to the technology. To access this interactive platform, and engage in live virtual clinical discussions, eye care professionals can request access here..

该倡议旨在促进医疗保健专业人员与早期获得该技术的专家外科医生之间就TECNIS Odyssey IOL进行直接而有意义的医学和科学对话。要访问此交互式平台并参与实时虚拟临床讨论，眼科专业人员可以在此处请求访问。。

TECNIS Odyssey IOL has also received regulatory authority approval in Japan, EU, Korea, Canada, Singapore, Australia and New Zealand.§§

TECNIS Odyssey IOL还获得了日本、欧盟、韩国、加拿大、新加坡、澳大利亚和新西兰监管机构的批准。§§

For more patient information and tools please visit www.clearvisionforyou.com and access the Vision Simulator which provides valuable insights into cataract surgery and treatment options. Eye care professionals can request more information here: TECNISOdysseyIOL.com.

有关更多患者信息和工具，请访问www.clearvisionforyou.com并访问视力模拟器，该模拟器为白内障手术和治疗选择提供了有价值的见解。眼科护理专业人士可以在这里索取更多信息：TECNISOdysseyIOL.com。

About Vision at Johnson & JohnsonJohnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. As a global leader in eye-health, we have a bold ambition: Vision Made Possible – and are paving the way for a new future of eye health to support the full spectrum of pediatric, developed and mature eyes.

关于强生公司的愿景强生公司在开发改善患者眼睛健康的变革性新产品方面有着深厚的传统。作为眼科健康领域的全球领导者，我们有一个大胆的雄心壮志：实现愿景，并为眼科健康的新未来铺平道路，以支持全方位的儿科、发达和成熟的眼睛。

Through cutting-edge innovation, scientific expertise, and advanced technologies, we are revolutionizing the way people see and experience the world. At every step of the eye health journey – from contact lenses and refractive and cataract surgical solutions to investigational gene therapies for retinal diseases – we stand as a trusted partner with the goal of making vision possible for customers and patients.

通过尖端创新、科学专业知识和先进技术，我们正在彻底改变人们看待和体验世界的方式。。

Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook..

访问jjvision.com，关注推特上的@JNJVision，LinkedIn上的Johnson＆Johnson Vision和Facebook上的@JNJVision。。

About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

关于强生公司在强生公司，我们相信健康就是一切。我们在医疗保健创新方面的优势使我们能够建立一个预防、治疗和治愈复杂疾病的世界，在这个世界上，治疗更加智能，侵入性更小，解决方案更加个性化。通过我们在创新医学和医学技术方面的专业知识，我们拥有独特的优势，可以在今天的所有医疗保健解决方案中进行创新，以实现明天的突破，并深刻影响人类的健康。

Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn..

了解更多有关我们医疗技术部门在心血管、骨科、外科和视力解决方案方面的全球规模和深厚专业知识https://thenext.jnjmedtech.com.请在@JNJMedTech和LinkedIn上关注我们。。

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS ODYSSEY™ IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODEL DRN00V AND TECNIS ODYSSEY™ TORIC II IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODELS DRT150, DRT225, DRT300, DRT375

TECNIS ODYSSEY™IOL（带TECNIS SIMPLICITY™输送系统）、DRN00V型和TECNIS ODYSSEY™TORIC II IOL（带TECNIS SIMPLICITY™输送系统）、DRT150、DRT225、DRT300、DRT375型的适应症和重要安全信息

Rx Only

仅接收

INDICATIONS:The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed.

适应症：TECNIS Simplication™输送系统用于折叠和协助插入TECNIS Odyssey™IOL，该IOL适用于成年患者无晶状体视力矫正的初次植入，其先前存在的角膜散光屈光度小于1，其中白内障晶状体已被移除。

The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed.

TECNIS Simplity™输送系统用于折叠并协助插入TECNIS Odyssey™Toric II人工晶状体，该人工晶状体用于初次植入，用于矫正无晶状体，并用于减少术前角膜散光屈光度大于或等于1的成年患者的屈光散光，其中白内障晶状体已被移除。

Compared to an aspheric monofocal lens, the TECNIS Odyssey™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only..

。该透镜仅用于胶囊袋放置。。

WARNINGS:Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starburst or glare around lights), which may be expected in nighttime or poor visibility conditions.

警告：人工晶状体可能会加剧现有疾病，可能会干扰疾病的诊断或治疗，或可能对患者的视力构成不合理的风险。患者应该有明确的视觉需求，并了解可能的视觉效果（例如光晕，星暴或灯光周围的眩光），这可能在夜间或能见度较差的情况下发生。

Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The physician should carefully weigh the potential risks and benefits for each patient. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear.

患者可能会认为这些视觉效果令人烦恼，在极少数情况下，这可能足以让患者要求移除人工晶状体。医生应仔细权衡每位患者的潜在风险和益处。预测术后残余散光大于1.0屈光度的患者，无论是否有复曲面镜片，在减少眼镜佩戴方面可能不会完全受益。

Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes.

TECNIS Odyssey™Toric II IOL从其预期轴的旋转可以减少其散光校正。错位大于30°可能会增加术后屈光圆柱。如有必要，应在透镜封装之前尽早进行透镜重新定位。。

Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design..

不这样做可能会导致镜头卡在墨盒中。不要试图拆卸、修改或更改输送系统或其任何部件，因为这可能会严重影响设计的功能和/或结构完整性。。

PRECAUTIONS:Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design.

注意事项：使用利用红外光的自动折射仪或波前像差仪或进行双色测试时，请谨慎解释结果。。进行某些眼部治疗（例如视网膜光凝）的能力可能会受到IOL光学设计的影响。

The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL.

外科医生应该瞄准正视眼，因为这种镜片是为实现正视眼时的最佳视觉表现而设计的。。小心地去除所有粘弹性材料，不要在箱子末端过度充气囊袋。囊袋的残留粘弹性和/或过度充气可能会使晶状体旋转，从而导致TECNIS Odyssey™Toric II IOL错位。

All preoperative surgical parameters are important when choosing a TECNIS Odyssey™ Toric II IOL for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, the surgeon's estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism.

选择TECNIS Odyssey™Toric II IOL进行植入时，所有术前手术参数都很重要，包括术前角膜曲率圆柱体（大小和轴），切口位置，外科医生估计的手术引起的散光（SIA）和生物测量。任何术前测量的变异性都会影响患者的预后以及治疗术前角膜散光量较低的眼睛的有效性。

The effectiveness of TECNIS Odyssey™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Odyssey™ IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism..

TECNIS Odyssey™Toric II人工晶状体在减少术前角膜散光<1.0屈光度患者术后残余散光方面的有效性尚未得到证实。预测术后散光大于1.0 D的患者可能不适合植入TECNIS Odyssey™人工晶状体，因为他们可能无法获得减少眼镜磨损或改善术后散光预测较低患者的中间和近视力的益处。。

ATTENTION:Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

注意：有关适应症和重要安全信息的完整列表，请参考使用说明。

Cautions Concerning Forward-Looking StatementsThis press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of TECNIS Odyssey intraocular lens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.

关于前瞻性声明的注意事项本新闻稿包含1995年《私人证券诉讼改革法案》中关于TECNIS Odyssey人工晶状体推出的“前瞻性声明”。提醒读者不要依赖这些前瞻性陈述。这些声明基于当前对未来事件的预期。

If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment.

如果基本假设不准确或出现已知或未知的风险或不确定性，实际结果可能与强生手术视力公司、强生视力护理公司和/或强生公司的预期和预测有很大差异。风险和不确定性包括但不限于：商业成功的不确定性；专利面临的挑战；竞争，包括技术进步、新产品和竞争对手获得的专利；制造困难和延误；导致产品召回或监管行动的产品功效或安全问题；适用法律法规的变更，包括全球医疗保健改革；医疗保健产品和服务购买者行为和支出模式的变化；以及医疗保健成本控制的趋势。

A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

。“风险因素”，以及强生公司随后在10-Q表上的季度报告以及向美国证券交易委员会提交的其他文件中。

Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Johnson & Johnson Surgical Vis.

这些文件的副本可在www.sec.gov、www.jnj.com或强生公司的要求下在线获得。没有强生外科手术。

©Johnson & Johnson and its affiliates 2024. All rights reserved.Third party trademarks are the property of their respective owners.

©强生公司及其附属公司2024。保留所有权利。第三方商标是其各自所有者的财产。

*According to ISO 11979-7:2024, based on the clinical study of the parent IOL† Based on pre-clinical bench testing

*根据ISO 11979-7:2024，基于基于临床前台架测试的母体IOL†的临床研究

‡ (n=82) 1-month results. Q: 'Was the patient wearing any spectacles or contact lenses since the surgery?' Six subjects 6/82 (5 subjects for near, 1 subject for both distance and near)¶ Compared to TECNIS Synergy™ and TECNIS™ Multifocal IOLs based on pre-clinical bench testing‖ Continuous 20/25 or better.# Individual results will vary.

‡（n=82）1个月的结果。Q： “手术后患者是否戴过眼镜或隐形眼镜？”6名受试者6/82（近距离5名受试者，距离和近距离1名受试者）¶与TECNIS Synergy™和TECNIS™多焦点人工晶状体相比，基于临床前台架测试‖连续20/25或更好个别结果会有所不同。

Some TECNIS Odyssey™ patients may require spectacles post-surgery.♠ Peter Menziuso is employed by Johnson & Johnson.** George Waring is a paid consultant of Johnson & Johnson Vision, Inc. For Contrast Sensitivity support, see References section5.†† Data on File. 2024DOF4003.‡‡ Data on File. DOF2023CT4052.¶¶ Compared to a leading competitor trifocal IOL based on pre-clinical bench testing§§ TECNIS Odyssey IOL will be available for select surgeons in countries across Japan, Korea, Canada, Singapore, Australia, New Zealand, Europe, Middle East & Africa (EMEA) through the LMR period, with expanded roll out expected in 2025 and beyond.§ Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both..

一些TECNIS Odyssey™患者在手术后可能需要戴眼镜。♠ Peter Menziuso受雇于强生公司。**George Waring是强生视觉公司的付费顾问。有关对比敏感度支持，请参阅参考文献第5节。††存档数据。2024DOF4003。‡‡数据存档。DOF2023CT4052。¶¶与领先的竞争对手相比，基于临床前台架测试的三焦人工晶状体§§TECNIS Odyssey人工晶状体将在LMR期间为日本，韩国，加拿大，新加坡，澳大利亚，新西兰，欧洲，中东和非洲（EMEA）国家的部分外科医生提供，预计2025年及以后将扩大推广。§强生视觉代表强生外科视觉公司、强生视觉护理公司及其附属公司的产品和服务。。

References

参考文献

1 Data on File. 2024DOF40022 Data on File. DOF2023CT40493 Data on File. DOF2023CT40564 Data on File. DOF2023CT40515 Data on File. 2024DOF40036 Data on File. DOF2023CT40237 Data on File. DOF2019OTH40028 Data on File. DOF2023CT40079 Data on File. DOF2023CT405010 CDC About Common Eye Disorders & Diseases (2024).

1存档数据。2024DOF40022数据存档。DOF2023CT40493文件中的数据。DOF2023CT40564文件中的数据。DOF2023CT40515文件中的数据。2024DOF40036数据存档。DOF2023CT40237文件中的数据。DOF2019OTH40028数据存档。DOF2023CT40079文件中的数据。DOF2023CT405010 CDC关于常见眼疾和疾病（2024）。

Access from: https://www.cdc.gov/vision-health/about-eye-disorders/11 American Academy of Ophthalmology (2024) Access from: https://www.aao.org/eye-health/diseases/what-is-presbyopia12 Data on File. 2024DOF400513 Data on File. 2024DOF402714 Data on File. 2024DOF402915 DFU for TECNIS Odyssey IOL; Data on File 2024DOF4030 (comparison of binocular, mesopic contrast sensitivity without-glare results from two bilateral implantation studies: 3-month post-op, ambispective, multicenter, observational clinical study of (n= 27) TECNIS Odyssey IOL and a 1-month post-op, prospective, multicenter, randomized, double-masked clinical study of (n=135) the parent IOL and (n=137) TECNIS Monofocal IOL).

https://www.cdc.gov/vision-health/about-eye-disorders/11美国眼科学会（2024）访问：https://www.aao.org/eye-health/diseases/what-is-presbyopia12文件中的数据。2024DOF400513数据存档。2024DOF402714数据存档。TECNIS Odyssey IOL的2024DOF402915 DFU；文件2024DOF4030中的数据（两项双侧植入研究的无眩光双目，中眼对比敏感度的比较：术后3个月，（n=27）TECNIS Odyssey IOL的双视，多中心，观察性临床研究和术后1个月，（n=135）母体IOL和（n=137）TECNIS单焦点IOL的前瞻性，多中心，随机，双盲临床研究）。

View original content:https://www.prnewswire.com/news-releases/johnson--johnson-rolls-out-new-tecnis-odyssey-next-generation-intraocular-lens-offering-cataract-patients-precise-vision-at-every-distance-in-any-lighting-302261636.html

查看原始内容：https://www.prnewswire.com/news-releases/johnson--johnson-rolls-out-new-tecnis-odyssey-next-generation-intraocular-lens-offering-cataract-patients-precise-vision-at-every-distance-in-any-lighting-302261636.html

SOURCE Johnson & Johnson

来源强生公司